Holen Sie sich die Stockscreener-App
0.00
100.00%
-12.58
Schlusskurs vom Vortag:
$12.58
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$718.13M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
0.00
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
0.00 | 718.13M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-17 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Bitget
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed? - Yahoo Finance
ATXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Spikes: Can Astria Therapeutics Inc ride the EV waveQuarterly Earnings Report & Community Verified Trade Signals - baoquankhu1.vn
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Insider Monkey
What are the future prospects of Astria Therapeutics Inc.2025 EndofYear Setup & Weekly High Potential Stock Alerts - mfd.ru
Can Astria Therapeutics Inc. ride the EV wave2025 Earnings Surprises & Technical Analysis for Trade Confirmation - mfd.ru
Is Astria Therapeutics Inc.’s ROE strong enoughTrade Volume Summary & Weekly Sector Rotation Insights - mfd.ru
BioCryst (BCRX) Poised for Growth with Key Acquisition and Positive Outlook - GuruFocus
Can Astria Therapeutics Inc. maintain its current growth rateJuly 2025 Trends & Capital Efficiency Focused Strategies - mfd.ru
Analyst Calls: Should I invest in Astria Therapeutics Inc before earnings2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy - MSN
Biocryst expands HAE treatment portfolio with Astria acquisition - Angioedema News
Can Astria Therapeutics Inc. stock beat market expectations this quarterMarket Movement Recap & Safe Capital Growth Plans - mfd.ru
Buyout Rumor: Can Astria Therapeutics Inc ride the EV waveEntry Point & Precise Trade Entry Recommendations - baoquankhu1.vn
Published on: 2026-01-28 20:41:53 - baoquankhu1.vn
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)? - Sahm
Bearish Setup: Can Astria Therapeutics Inc. reach all time highs this yearMarket Sentiment Report & Fast Gaining Stock Reports - mfd.ru
Breakouts Watch: What dividend growth rate does Astria Therapeutics Inc offer2025 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Liquidity Mapping Around (ATXS) Price Events - Stock Traders Daily
Option Delisting: Astria Therapeutics (ATXS) to be Delisted - GuruFocus
BioCryst Completes Acquisition of Astria Therapeutics - Longbridge
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Sahm
Astria Therapeutics Completes Merger and Goes Private - TipRanks
Astria Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
BioCryst completes $700 million acquisition of Astria Therapeutics By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics to Enhance HAE Portfolio - Quiver Quantitative
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Hedge Fund Bets: Is Astria Therapeutics Inc trading at a discount2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Short Interest in Astria Therapeutics, Inc. (NASDAQ:ATXS) Increases By 37.9% - MarketBeat
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Why (ATXS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® - GlobeNewswire
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - Yahoo Finance
Why Astria Therapeutics Inc. stock could outperform in 20252025 Major Catalysts & Free Long-Term Investment Growth Plans - ulpravda.ru
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - sharewise.com
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - PR Newswire
Growth Recap: Is Astria Therapeutics Inc stock in correction or buying zone2025 Trade Ideas & Consistent Profit Focused Trading Strategies - Bộ Nội Vụ
Understanding Momentum Shifts in (ATXS) - Stock Traders Daily
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.71%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):